TABLE 1.

Oligonucleotides designed for this study

Primer name	Oligonucleotide sequence (5′-3′)a
EVS62	CTT CAG ATC CTC TAC GCC GGA CGC
EVS90	GGG AGA TCT GTC GACCTG TCT CTT ATA CAC ATC TGC GGC CGC TCT AGA ACT AGT GGA TCC
EVS91	GGG AGA TCT GTC TCT TAT ACA CAT CTA AGG TAA TCA GGA GCT AAG GAA GCT AAA ATG G
EVS92	CCC GGA TCC GTA GCG TCC TGA ACG GAA CCT TTC CCG
M13LKF	CTA GGG GCC CTG TAA AAC GAC GGC CAG TC
M13LKR	CTA GGA CTG GCC GTC GTT TTA CAG GGC CC

^aOptimized 19-bp Tn5 mosaic ends (5′-CTG TCT CTT ATA CAC ATC T-3′) are indicated by single underlines in EVS90 and EVS91. The M13 Forward priming site (5′-TGT AAA ACG ACG GCC AGT-3′) and its complement formed by annealing M13LKF and M13LKR together are underlined in those sequences. Translational stops (5′-TAA-3′), present in all three potential reading frames in EVS91, are shown in boldface. Key restriction enzyme recognition sequences are in italics, including ApaI (5′-GGGCC/C-3′) in M13LKF and M13LKR, BamHI (5′-G/GATCC-3′) in EVS92, BglII (5′-A/GATCT-3′) in EVS90 and EVS91, and SalI (5′-G/TCGAC-3′) in EVS90.